Subjective cognitive decline is a quiet, often unsettling experience. A person notices that their memory or thinking feels different, yet every test they take is labeled “normal.” They may forget conversations more often, lean on reminder notes in ways they never used to, or sense that everyday thinking takes more effort. These changes can be easy to dismiss, but they may also represent an early window into Alzheimer’s prevention and treatment.

Geriatrician and memory-care physician Dr. Nathaniel Chin has spent years listening to people who feel this kind of gap between their lived experience and their test results. As medical director and Clinical Core co-leader of the Wisconsin Alzheimer’s Disease Research Center, and as someone shaped by caring for a parent with early-onset Alzheimer’s, he argues that this stage deserves much more attention. The term used in research and clinical care is “subjective cognitive decline,” or SCD. It describes a persistent sense that one’s cognitive abilities have slipped compared with the past, while careful cognitive testing still falls in the expected range for age.

That last part is crucial. Many people only receive brief screening tests that take five to fifteen minutes and sample just a small slice of cognition. These tools are useful for identifying clear cognitive impairment, but they cannot match the depth of a comprehensive cognitive evaluation. A more thorough assessment typically lasts an hour or longer and examines memory, language, attention, executive function, and other thinking skills in detail. For SCD to be diagnosed meaningfully, a clinician needs enough data to be reasonably confident that objective impairment is not already present.

Even with extensive testing, though, there is a catch. Cognitive scores are usually compared with others of similar age, not with a person’s own prior level. Someone who started from a very high baseline can decline in a way that feels dramatic to them and their family, yet still land in the statistical “average” range. Dr. Chin points to situations such as a retired engineer whose once exceptional abilities settle into mid-range scores. Repeated testing becomes invaluable in these cases. Establishing a baseline allows clinicians to track whether a person remains stable or shows a consistent downward trend long before numbers cross into the impaired range.

Subjective cognitive decline itself is not a diagnosis of Alzheimer’s disease. Instead it is a description of what a person is reporting. Many factors can affect how sharp thinking feels, including poor sleep, medications, depression, anxiety, medical illness, vascular disease, hearing loss, stress, and typical aging. Still, researchers have worked to identify when SCD should raise more concern about early Alzheimer’s.

Psychiatrist Dr. Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative developed a set of features known as “SCD plus.” These are characteristics that make it more likely that subjective decline reflects early Alzheimer’s changes. They include memory-focused problems, onset within the past five years, onset at age 60 or older, ongoing worry about the changes, persistence over time, seeking medical attention because of them, and confirmation from someone who knows the person well. None of these factors can prove the presence of Alzheimer’s disease. When several cluster together, however, they justify closer evaluation.

To illustrate why context matters, Dr. Chin invites us to imagine two individuals. One has sporadically worried about finding the right word for the past fifteen years, starting in their late 40s, with concerns surfacing mainly after poor sleep or during stressful periods. The other, in their 60s, describes a clear decline in memory over the last two years, feels worried enough to seek an assessment, has a spouse who has noticed the same change, and continues to report it at follow-up visits. Both people may achieve normal scores on cognitive testing, yet their clinical pictures are not equal. The second person fits more of the SCD-plus features, and that distinction should shape how a clinician responds.

Dr. Chin argues that for someone with persistent subjective cognitive decline, particularly when several SCD-plus characteristics are present, it is not enough to say, “Your testing is normal. Come back if it gets worse.” Instead, he recommends building a thorough cognitive baseline, exploring other contributors such as sleep, mood, and medications, gathering input from a close friend or family member when possible, and repeating cognitive testing over time to look for patterns.

In selected situations, modern biomarkers can add important information. Blood tests, cerebrospinal fluid analysis, and amyloid PET scans can reveal whether the biological changes associated with Alzheimer’s disease are present before a person reaches mild cognitive impairment or dementia. A positive biomarker result in someone without objective impairment does not confirm that Alzheimer’s is driving their symptoms or predict an exact timeline of decline. Nor does it qualify them for an approved Alzheimer’s drug at this stage. It does, however, signal a higher risk of future impairment and shifts how a clinician thinks about risk and monitoring.

This is where subjective cognitive decline sits at a meaningful crossroads between Alzheimer’s prevention and treatment. On one side lies traditional prevention, focused on reducing risks before any noticeable decline. On the other lies treatment of mild cognitive impairment or dementia due to Alzheimer’s, once objective deficits can be measured. SCD occupies the space between those ends. A person feels that something has changed, yet formal tests still look normal. For some, Alzheimer’s-related biology may already be active.

Currently there is no approved Alzheimer’s medication specifically for people in the SCD stage. Amyloid-targeting therapies such as lecanemab and donanemab are available only for individuals with mild cognitive impairment or mild dementia due to Alzheimer’s. However, major prevention trials like the AHEAD 3-45 Study and TRAILBLAZER-ALZ 3 are testing whether treating people earlier, while they are still classified as cognitively unimpaired, can delay the onset of measurable decline. Some participants in these trials likely have subjective cognitive changes even though they do not yet meet criteria for impairment.

That evolving research landscape underscores why SCD is more than a diagnostic curiosity. It may represent one of the earliest clinical opportunities to recognize Alzheimer’s disease and act before functional losses become obvious. For now, that opportunity includes addressing cardiovascular risks, increasing physical activity, improving sleep, treating hearing loss, reviewing medications for cognitive side effects, and supporting overall brain health. It also includes following cognition over time, using Alzheimer’s biomarkers when clinically appropriate, and connecting interested individuals with research studies.

For people who notice concerning changes in their memory or thinking and are told their testing is normal, several steps can be helpful. They can ask whether a more comprehensive cognitive evaluation is appropriate instead of relying solely on a brief screen. Bringing someone who knows them well to the appointment can provide valuable corroboration. It can also be useful to ask about other factors that might affect thinking, including sleep quality, mood, and hearing, and to request that current test results be treated as a baseline for future comparison. Those open to research can inquire about clinical studies at Alzheimer’s disease research centers, many of which enroll people both with and without cognitive impairment.

The underlying message is that “early” should not be defined as the moment someone finally scores poorly enough on a cognitive test to meet criteria for mild cognitive impairment. Listening carefully when people say they have changed, evaluating them thoroughly enough to determine whether objective deficits exist, establishing a baseline, and, when appropriate, using biomarkers to test for Alzheimer’s biology can all bring the field closer to true early detection. Subjective cognitive decline does not automatically equal Alzheimer’s disease. For some people, though, it may be the earliest signpost that allows clinicians and individuals to respond before measurable impairment appears. Read more at https://beingpatient.com/subjective-cognitive-decline-early-alzheimers-prevention-treatment/